SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize.
• 2 Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta.
• 3 Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: